Mirtazapine

Study	Exclusion reasons	Rmk	Reference
Kjaersgaard (Controls unexposed, NOS), 2013		For Mirtazapine: overlapping for Early intrauterine death between Ostenfeld 2022 (1997-2016) and Kjaersgaard, 2013 (1997-2008), based on the same databases. Ostenfeld that use adjustment and based on a longer study period reported rather than Kjaersgaard.	Kjaersgaard PLoS One 2013; 8:e72095 10.1371/journal.pone.0072095
Kjaersgaard (Controls unexposed, sick), 2013		For Mirtazapine: overlapping for Early intrauterine death between Ostenfeld 2022 (1997-2016) and Kjaersgaard, 2013 (1997-2008), based on the same databases. Ostenfeld that use adjustment and based on a longer study period reported rather than Kjaersgaard.	Kjaersgaard PLoS One 2013; 8:e72095 10.1371/journal.pone.0072095
Lennestal, 2007	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: analysis of SNRI/NRI as a whole (with a majority of Venlafaxine).	Lennestal J Clin Psychopharmacol 2007; 27:607-13 10.1097/jcp.0b013e31815ac4d2
Manakova, 2011	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: analysis of 'new atypical antidepressants and antipsychotics' as a whole, without distinction between treatments (APD (risperidone, mirtazapine, venlafaxine, trazodone, aripiprazole, ziprasidone, olanzapine).	Manakova Neuro Endocrinol Lett 2011; 32 Suppl 1:53-6
Nakhai-Pour, 2010	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: analysis of antidepressant class and some individual antidepressant but not Mirtazapine.	Nakhai-Pour CMAJ 2010; 182:1031-7 10.1503/cmaj.091208